Novo Nordisk Receives Marketing Authorisation For Victoza
Published: 03-Jul-2009
Victoza, once-daily human Glucagon-Like Peptide-1 analogue, developed for the treatment of type 2 diabetes
European Commission has granted marketing authorisation for Novo Nordisk' Victoza, for the treatment of type 2 diabetes in adults. The authorisation covers all 27 EU member states.
Victoza is the brand name approved in Europe for liraglutide, the once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.
Mads Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, said: This is an important milestone for Novo Nordisk and for the treatment of type 2 diabetes. In clinical studies involving more than 6,500 people with type 2 diabetes, Victoza has been shown to have a significant blood glucose-lowering effect and lead to weight loss, while having a low risk of hypoglycaemia. On this background, we are convinced that Victoza is a valuable new treatment option for people with type 2 diabetes.
Novo Nordisk would launch Victoza in the UK, Germany and Denmark during the summer, and in other European markets during the second half of 2009 and throughout 2010.
Network Sites

Suppliers To This Sector
Browse A-Z
Almac
Drug Development Solutions ...
STARLIMS
Benefits for Life Science Labs ...
Parenteral Drug Association (PDA)
Pharmaceutical Information and Education Services ...
Burkert Fluid Control Systems
Fluid and Gas Control Systems ...
IMCOR
LIMS and Laboratory Informatics Consultancy ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully